Alpa Laboratorie

Why is Alpa Laboratories Ltd falling/rising?

As of 31-Jul, Alpa Laboratories Ltd's stock price is at 66.03, down 1.97%, and has underperformed against the Sensex, which has risen by 2.68% over the past week. The stock is on a downward trend, having fallen 14.68% year-to-date and trading below all key moving averages.

As of 31-Jul, Alpa Laboratories Ltd's stock price is falling, currently at 66.03, which reflects a decrease of 1.33 or 1.97%. The stock has underperformed compared to the benchmark Sensex, which has risen by 2.68% over the past week, while Alpa Laboratories has declined by 1.45%. Over the past month, the stock has fallen by 3.63%, in contrast to the Sensex's gain of 1.52%. Year-to-date, the stock is down 14.68%, significantly worse than the Sensex's decline of 8.36%. <BR><BR>The stock has been on a downward trend, having fallen consecutively for the last two days, with a total decline of 4.29% during this period. It also reached an intraday low of Rs 65.55, marking a decrease of 2.69%. Furthermore, Alpa Laboratories is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 21.8% against the 5-day average, the overall performance remains negative, contributing to the stock's decline.

Which are the latest news on Alpa Laboratorie?

How big is Alpa Laboratorie?

As of 10th June, Alpa Laboratories Ltd has a market capitalization of 147.00 Cr, with net sales of 105.82 Cr and a net profit of 14.85 Cr reported in the latest four quarters.

As of 10th June, Alpa Laboratories Ltd has a market capitalization of 147.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Alpa Laboratories reported net sales of 105.82 Cr and a net profit of 14.85 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 171.43 Cr and total assets of 222.63 Cr.

Who are in the management team of Alpa Laboratorie?

The management team of Alpa Laboratorie includes Chairman Mahendra Singh Chawla, Managing Director Paresh Chawla, and several executive directors, along with independent directors and Company Secretary Swati Bagh, providing a blend of leadership and oversight.

The management team of Alpa Laboratorie includes the following members:<BR><BR>1. **Mahendra Singh Chawla** - Chairman & Executive Director<BR>2. **Paresh Chawla** - Managing Director<BR>3. **Pravin C Shah** - Executive Director<BR>4. **Vitthal Kothana** - Executive Director<BR>5. **Sunil Valecha** - Additional Director<BR><BR>Additionally, the board has several independent directors:<BR>1. **Sharad Chand Lunawat** - Independent Director<BR>2. **Devendra Baheti** - Independent Director<BR>3. **Krishna Das Malani** - Independent Director<BR>4. **Jyoti Jain** - Independent Director<BR>5. **Saket Baheti** - Independent Director<BR>6. **Pratibha Lunawat** - Independent Director<BR><BR>Lastly, **Swati Bagh** serves as the Company Secretary & Compliance Officer. This diverse team brings a mix of executive leadership and independent oversight to the company.

Who are the peers of the Alpa Laboratorie?

Alpa Laboratorie's peers include Kimia Bioscien., Achyut Healthcar, Parnax Lab, Krebs Biochem, Bal Pharma, Smruthi Organic, Lactose (India), Tyche Industries, and Accretion Pha. Management risk varies from excellent at Accretion Pha. to below average at Kimia Bioscien., with Alpa Laboratorie's 1-year return at -32.55%, lower than peers like Achyut Healthcar, which has the highest return at 71.17%.

Peers: The peers of Alpa Laboratorie are Kimia Bioscien., Achyut Healthcar, Parnax Lab, Krebs Biochem, Bal Pharma, Smruthi Organic, Lactose (India), Tyche Industries, Accretion Pha., and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Accretion Pha., while Average management risk is found at Alpa Laboratorie, Bal Pharma, Smruthi Organic, and Tyche Industries, and the rest. Below Average management risk is noted for Kimia Bioscien., Achyut Healthcar, Parnax Lab, Lactose (India), and the rest. Growth is Excellent at Lactose (India) and Accretion Pha., Good at Parnax Lab and Achyut Healthcar, Average at Alpa Laboratorie, Bal Pharma, Smruthi Organic, and Tyche Industries, and the rest, while Below Average growth is seen in Kimia Bioscien. and the rest. Capital Structure is Excellent at Parnax Lab and Alpa Laboratorie, Good at Achyut Healthcar and Smruthi Organic, Below Average at Kimia Bioscien., Bal Pharma, Lactose (India), Tyche Industries, and the rest.<BR><BR>Return Snapshot: Achyut Healthcar has the highest 1-year return at 71.17%, while Krebs Biochem has the lowest at -29.43%. Alpa Laboratorie's 1-year return of -32.55% is lower than both. Additionally, the six-month returns are negative for Krebs Biochem, Alpa Laboratorie, Smruthi Organic, Lactose (India), Tyche Industries, and Bal Pharma.

What does Alpa Laboratorie do?

Alpa Laboratories Ltd is a micro-cap pharmaceutical and biotechnology company founded in 1967, specializing in manufacturing various pharmaceutical formulations. As of March 2026, it reported net sales of 31 Cr and a net profit of 1 Cr, with a market cap of INR 147 Cr.

Overview:<BR>Alpa Laboratories Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market, specializing in the manufacture of various pharmaceutical formulations.<BR><BR>History:<BR>Alpa Laboratories was incorporated in 1967 as 'Alpa Laboratories Private Limited' on March 18, 1988, and was converted into a Public Limited Company on September 3, 1998. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 31 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 147 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 10.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.73<BR>- Return on Equity: 7.97%<BR>- Price to Book: 0.78<BR><BR>Contact Details:<BR>Address: 33/2 Pigdamber, A B Road Rau Indore Madhya Pradesh : 453446<BR>Tel: 91-731-4294567<BR>Email: is@alpalabs.com<BR>Website: http://www.alpalabs.in

Should I buy, sell or hold Alpa Laboratories Ltd?

Are Alpa Laboratories Ltd latest results good or bad?

Alpa Laboratories Ltd's latest results are largely negative, with a 78.65% decline in net profit to ₹1.90 crore despite an 11.09% increase in revenue to ₹29.05 crore. The stock fell over 6% post-announcement, indicating reduced investor confidence amid concerns about profitability and sustainability.

Alpa Laboratories Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q3 FY26, the company reported a net profit of ₹1.90 crore, which is a significant decline of 78.65% year-on-year. This sharp drop in net profit raises concerns about the company's profitability and operational stability.<BR><BR>On the positive side, revenue for the same quarter increased by 11.09% year-on-year, reaching ₹29.05 crore. This indicates some ability to grow sales, but the overall performance is overshadowed by the drastic fall in net profit. Additionally, the operating margin improved to 5.23% from a negative margin in the previous quarter, which is a positive sign, but still below historical levels.<BR><BR>The company's reliance on other income to support profitability is a critical concern, as it raises questions about the sustainability of its business model. The stock has reacted negatively to these results, declining over 6% in the trading session following the announcement, reflecting diminished investor confidence.<BR><BR>In summary, while there are some signs of revenue growth, the substantial decline in net profit and ongoing operational challenges suggest that the latest results are more bad than good for Alpa Laboratories Ltd.

When is the next results date for Alpa Laboratories Ltd?

The next results date for Alpa Laboratories Ltd is 11 February 2026.

The next results date for Alpa Laboratories Ltd is scheduled for 11 February 2026.

Is Alpa Laboratorie overvalued or undervalued?

As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.

As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure.<BR><BR>In comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation.

How has been the historical performance of Alpa Laboratorie?

Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.

Answer:<BR>The historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses.<BR><BR>Breakdown:<BR>Alpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profitability. The company's total assets grew from 120.43 Cr in Mar'20 to 222.63 Cr in Mar'25, with total liabilities also increasing from 120.43 Cr to 222.63 Cr in the same period. Cash flow from operating activities improved significantly to 18.00 Cr in Mar'25, compared to just 3.00 Cr in Mar'24, reflecting better operational efficiency. Overall, Alpa Laboratorie's financial performance demonstrates a positive growth trajectory despite rising costs and fluctuating profit margins.

Who are the top shareholders of the Alpa Laboratorie?

The top shareholders of Alpa Laboratorie include promoter Paresh Chawla with 34.26%, individual investors with 37.28%, and two foreign institutional investors holding 0.36%. There are no mutual funds or pledged promoter holdings in the company.

The top shareholders of Alpa Laboratorie are primarily its promoters, with Paresh Chawla being the individual with the highest holding at 34.26%. Additionally, individual investors collectively hold 37.28% of the shares. There are also two foreign institutional investors (FIIs) that hold a combined total of 0.36%. Notably, there are no mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Alpa Laboratorie?

As of June 5, 2025, Alpa Laboratorie's trend has shifted to bearish with moderate strength, driven by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and KST.

As of 5 June 2025, the technical trend for Alpa Laboratorie has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and mildly bearish signals from Bollinger Bands and Dow Theory on both weekly and monthly time frames. The KST shows a mildly bullish trend on the weekly but remains mildly bearish monthly, indicating mixed signals. Overall, the bearish trend is reinforced by the recent price action and the performance relative to the Sensex.

Has Alpa Laboratorie declared dividend?

No Dividend History Available